Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists

Fernández‐Nebro, Antonio; Tomero, Eva; Ortiz-Santamaría, Vera; Castro, M.C.; Olivé, Alejandro; Haro, M de; Garcia-Vicuna, R.; González-Mari, María Victoria; Laffón, A; García‐Vicuña, Rosario

doi:10.1016/j.amjmed.2005.01.028

Cited by 90 publications

(49 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well known that secondary amyloidosis occurs in patients with poorly controlled RA. Previous studies have demonstrated that infliximab therapy is useful for treating amyloid nephropathy associated with RA, although its curative effects vary (6,7). Furthermore, several recent case reports have demonstrated the effects of anti-TNF-α therapy in patients with amyloid nephropathy associated with CD (8-13) (Table).…”

Section: Discussionmentioning

confidence: 99%

Successful Use of Maintenance Infliximab for Nephropathy in a Patient with Secondary Amyloidosis Complicating Crohn's Disease

et al. 2013

View full text Add to dashboard Cite

Systemic AA amyloidosis is a complication of various inflammatory diseases including Crohn's disease (CD). Amyloid nephropathy is the most common clinical presentation of AA amyloidosis leading to renal failure, and affected patients often require hemodialysis and ultimately renal transplantation. We herein report the successful use of infliximab as maintenance therapy for amyloid nephropathy in a patient with CD. In the present patient, surgical treatment and infliximab infusion immediately induced a remission of CD, and scheduled infliximab therapy successfully maintained the patient's stable condition for three years, with a significant decrease in the serum creatinine level.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Use of Maintenance Infliximab for Nephropathy in a Patient with Secondary Amyloidosis Complicating Crohn's Disease

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Series of cases have described the efficacy of anti-TNFα therapy in patients with AA amyloidosis secondary to rheumatic diseases, probably due to the prompt and sustained clinical remission of RA. 1,6 Improvement seems to be related to inhibition of TNF-induced hepatic production of AA amyloid and deposition. 1 Thus, biological agents represent and alternative for the control of amyloidosis secondary to RA 6,7 .…”

Section: Discussionmentioning

confidence: 99%

“…1,6 Improvement seems to be related to inhibition of TNF-induced hepatic production of AA amyloid and deposition. 1 Thus, biological agents represent and alternative for the control of amyloidosis secondary to RA 6,7 . Gottenberg et al 14 and Elkayam et al 15 demonstrated a reduction in proteinuria and stabilization of the kidney function in patients with RA and spondyloarthritis in patients on anti-TNFα therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Clinical assays are necessary to determine the impact of this treatment on secondary amyloidosis, evaluating its safety and efficacy. 6 Summarizing, the presence of amyloidosis as a secondary complication of RA implies on marked morbidity and mortality, and the use of anti-TNFα agents represent a promising therapeutic alternative for the control of the rheumatic and renal diseases. …”

Section: Discussionmentioning

confidence: 99%

“…Due to the possibility of controlling the inflammatory activity, anti-TNF agents represent and alternative treatment of secondary types. 6,7 The Brazilian Journal of Rheumatology has published three cases of amyloidosis, two on primary amyloidosis 3,8 and one secondary to hemodialysis, 9 over the last ten years. The objective of this report was to illustrate secondary renal amyloidosis as a rare complication of RA, and to discuss the use of anti-TNFα (etanercept) agents as a new therapeutic perspective.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Terapia com anti-TNF na amiloidose renal em artrite reumatoide refratária: uma nova perspectiva terapêutica

Nobre¹,

Callado²,

Rodrigues³

et al. 2010

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Amyloidosis is a heterogeneous group of diseases characterized by extracellular deposits of a material composed of aggregates of amyloid -a poorly coupled protein -far from the site of synthesis, causing target organ dysfunction and clinical disease. Systemic amyloidosis A (AA), secondary to infections and chronic inflammation, especially rheumatoid arthritis (RA), is the most common form of amyloid deposition. Treatment of AA consists in the control or resolution of the baseline condition. The objective of the present study was to report a case of secondary renal amyloidosis in a patient with long-term refractory RA who presented sustained clinical improvement after the use of anti-TNFα (etanercept).

show abstract

Systemic amyloidosis with Crohnʼs disease treated with infliximab

Park

Han

Eun

2008

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists

Cited by 90 publications

References 17 publications

Successful Use of Maintenance Infliximab for Nephropathy in a Patient with Secondary Amyloidosis Complicating Crohn's Disease

Successful Use of Maintenance Infliximab for Nephropathy in a Patient with Secondary Amyloidosis Complicating Crohn's Disease

Terapia com anti-TNF na amiloidose renal em artrite reumatoide refratária: uma nova perspectiva terapêutica

Systemic amyloidosis with Crohnʼs disease treated with infliximab

Contact Info

Product

Resources

About